Company pipeline · women's health

Astellas women's health pipeline

Astellas is the lead sponsor of 4 active trials in the conditions TrialsForHer tracks (Menopause), 2 of them open to recruitment now or about to open.

Data pulled 21 Oct 2026Sources: ClinicalTrials.gov + EU CTISAll company pipelines

2open or about to open

4active trials (incl. recruitment ended)

1tracked condition

28 Feb 2027next registry-reported primary completion (est.)

Trials

Open trials first, then by primary completion date. Phases: Phase 3: 3, Observational: 1. "est." marks the sponsor's estimated date; CTIS search results don't include primary completion dates. Registry sponsor names grouped here: Astellas Pharma Europe Ltd.; Astellas Pharma Global Development Inc.; Astellas Pharma Global Development, Inc.; Astellas Pharma Inc.

ID	Title	Condition	Lead sponsor	Phase	Status	Primary completion	Enrolment	Site countries
NCT07602530 ClinicalTrials.gov	A Study in Canada to Follow Outcomes of Women in Menopause Treated With Fezolinetant for Hot Flashes, When Given in Clinical Practice	Menopause	Astellas Pharma Europe Ltd.	Observational	Recruiting	28 Feb 2027 (est.)	238	Canada
NCT07829653 ClinicalTrials.gov	A Study to Confirm if Fezolinetant Helps to Reduce Hot Flashes in Indian Women Going Through Menopause	Menopause	Astellas Pharma Inc	Phase 3	Not yet recruiting	31 Mar 2028 (est.)	100	—
NCT06440967 ClinicalTrials.gov	A Study to Confirm if Fezolinetant Helps Reduce Hot Flashes in Women With Breast Cancer Who Are Having Hormone Therapy	Menopause	Astellas Pharma Global Development, Inc.	Phase 3	Active, not recruiting	25 Jun 2026	982	Canada, Czechia, Denmark, France +7
2024-510719-31-00 EU CTIS	A Randomized, Placebo-controlled, Double-blind, Phase 3 Clinical Study to Investigate the Efficacy and Safety of Fezolinetant for Treatment of Moderate to Severe Vasomotor Symptoms (Hot Flashes) in Women with Stage 0 to 3 Hormone Receptor-positive Breast Cancer Who Are Receiving Adjuvant Endocrine Therapy	Menopause	Astellas Pharma Global Development Inc.	Phase 3	Ongoing, recruitment ended	—	—	Czechia, Denmark, France, Germany +5

Free weekly digest

Track women's-health pipelines every Monday

New trials, phase changes, stopped trials and new sponsors across the conditions we track, with registry links.

Your ticks help us prioritise what to build. They don't commit you to anything, and no payment is taken.

Want biotech news too? Closewire: nightly recap of what moved in Tech and Health stocks, plus a free Sunday weekly. Subscribe to Closewire →

Business research data, not medical advice. TrialsForHer summarises public registry records from ClinicalTrials.gov and the EU Clinical Trials Information System (CTIS) for professional and research use. Registry entries can be incomplete or out of date, and dates marked "est." are the sponsor's own estimates. Always check the official record. This isn't a way to enrol in a study; patients and carers should talk to their clinician or the study team listed on the registry.